Edition:
United Kingdom

Supernus Pharmaceuticals Inc (SUPN.OQ)

SUPN.OQ on NASDAQ Stock Exchange Global Market

39.05USD
22 Nov 2017
Change (% chg)

$0.35 (+0.90%)
Prev Close
$38.70
Open
$38.75
Day's High
$39.35
Day's Low
$38.65
Volume
92,205
Avg. Vol
188,891
52-wk High
$50.03
52-wk Low
$20.60

Latest Key Developments (Source: Significant Developments)

Supernus announces third quarter 2017 financial results
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Supernus Pharmaceuticals Inc :Supernus announces third quarter 2017 financial results.Q3 earnings per share $0.29.Q3 earnings per share view $0.27 -- Thomson Reuters I/B/E/S.Sees full year 2017 net product sales guidance range to $290 million to $295 million​.Sees ‍FY 2017 operating income in range of $85 million to $90 million​.  Full Article

Supernus pharmaceuticals Inc says FY 2016 net product sales will remain in range of $200 mln- $210 mln
Tuesday, 2 Aug 2016 

Supernus Pharmaceuticals Inc : Supernus announces second quarter 2016 financial results . Q2 revenue $50.4 million versus I/B/E/S view $49.7 million . Q2 earnings per share $0.18 . Q2 earnings per share view $0.13 -- Thomson Reuters I/B/E/S . Sees 2016 operating income in range of $32 million to $37 million . For full year 2016, company is reiterating guidance for net product sales .Supernus pharmaceuticals inc says fy 2016 net product sales will remain in range of $200 million to $210 million.  Full Article

Supernus reiterates guidance
Thursday, 16 Jun 2016 

Supernus Pharmaceuticals Inc : Remains in discussions with FDA regarding its supplemental new drug application, or SNDA, for migraine . Believes that such a PDUFA date is likely to be in Q3 of 2016 . FDA requested that co resubmit Trokendi XR product label with migraine as indication in different format before completing its review . No additional new data, studies or analyses for efficacy or safety were requested by FDA . Will resubmit revised label before end of June . New PDUFA date will be assigned by FDA . At this point, company believes that such a PDUFA date is likely to be in Q3 of 2016 . For full year 2016, company reiterates its guidance for net product sales and operating income .Supernus provides update on Trokendi XR migraine SNDA and reiterates guidance.  Full Article

Supernus enters partial settlement agreement with Actavis on oxtellar xr
Tuesday, 10 May 2016 

Supernus Pharmaceuticals Inc : Supernus enters into partial settlement agreement with Actavis on oxtellar xr .Partial settlement of pending patent infringement dispute with Actavis will eliminate substantial litigation costs.  Full Article